Center of Excellence for Flow Cytometry, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
J Acquir Immune Defic Syndr. 2010 Jan;53(1):47-54. doi: 10.1097/QAI.0b013e3181c4b8ae.
CD4(+) T-lymphocyte count is an important marker in management of HIV-1-infected patients. The standard single-platform (SP) flow cytometric (FCM) CD4(+) testing that uses the known reference microbeads is expensive; more affordable alternatives are therefore needed. We evaluated the use of glutaraldehyde-fixed chicken red blood cells (CRBCs) as counting beads as an alternative for enumerating CD4(+) T-lymphocyte counts in 87 HIV-1-infected patients. Linear regression analyses revealed an excellent correlation of the SP FCM using CRBCs with the standard SP bead-based FCM method (percentages, r(2) > 0.99; absolute counts, r(2) > 0.98) over the entire range including the clinically relevant range. Mean percent bias for the CRBC method was +0.35% [limits of agreement (LOA): -1.86% to +2.57%]. For absolute CD4(+) T-lymphocytes, the mean biases was -47.76 cells per microliter (LOA: -191.34 to +98.81 cells/microL) with much lower bias for CD4 T-lymphocyte counts <200 cells per microliter (LOA: -31.92 to +22.95 cells/microL). The use of CRBCs is comparable with the use of commercial microbeads. This has resulted in major cost savings to resource-limited countries where the health care system is under increasing pressure to operate cost effectively. This can greatly facilitate and ensure the success of the ongoing antiretroviral therapy program in these countries.
CD4(+) T 淋巴细胞计数是 HIV-1 感染患者管理的重要标志物。使用已知参考微球的标准单平台(SP)流式细胞术(FCM)CD4(+) 检测费用昂贵;因此,需要更经济实惠的替代方法。我们评估了戊二醛固定鸡红细胞(CRBC)作为计数珠在 87 例 HIV-1 感染患者中计数 CD4(+) T 淋巴细胞的用途。线性回归分析显示,使用 CRBC 的 SP FCM 与标准基于 SP 珠的 FCM 方法(百分比,r(2) > 0.99;绝对计数,r(2) > 0.98)在整个范围内具有极好的相关性,包括临床相关范围。CRBC 方法的平均百分比偏差为+0.35%[允许偏差(LOA):-1.86%至+2.57%]。对于绝对 CD4(+) T 淋巴细胞,平均偏差为 -47.76 个细胞/微升(LOA:-191.34 至+98.81 个细胞/微升),而 CD4 T 淋巴细胞计数<200 个细胞/微升时的偏差要小得多(LOA:-31.92 至+22.95 个细胞/微升)。CRBC 的使用与商业微球的使用相当。这为资源有限的国家节省了大量成本,这些国家的医疗保健系统面临着越来越大的成本效益运营压力。这将极大地促进和确保这些国家正在进行的抗逆转录病毒治疗计划的成功。